Bavarian Nordic A/S 

$29.71
330
-$0.97-3.16% Monday 16:20

Statistics

Day High
30.68
Day Low
30.68
52W High
37.6
52W Low
20.71
Volume
100
Avg. Volume
58
Mkt Cap
0
P/E Ratio
13.22
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.23
0.57
1.36
2.15
Expected EPS
N/A
Actual EPS
N/A

Financials

17.08%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
1.61BRevenue
275.59MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BVNKF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc is a competitor due to its involvement in the development and marketing of vaccines and pharmaceuticals, similar to Bavarian Nordic's focus areas.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. competes in the vaccine space, particularly in mRNA vaccines, which could overlap with Bavarian Nordic's infectious disease portfolio.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a direct competitor in the pharmaceutical and vaccine market, including efforts in infectious diseases that Bavarian Nordic targets.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson operates in the same pharmaceutical and vaccine sectors, making it a competitor to Bavarian Nordic, especially in the area of infectious diseases.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is involved in the development of vaccines and pharmaceuticals for infectious diseases, competing with Bavarian Nordic's product offerings.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE, known for its mRNA vaccines, competes in the vaccine market, particularly in areas that overlap with Bavarian Nordic's focus.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. specializes in the development of vaccines, including for COVID-19 and influenza, making it a competitor in Bavarian Nordic's market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC competes in various pharmaceutical areas, including the development of vaccines for infectious diseases, similar to Bavarian Nordic's focus.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a competitor due to its extensive pharmaceutical products and vaccines, including for diseases that Bavarian Nordic also targets.
Arbutus Biopharma
ABUS
Mkt Cap906.73M
Arbutus Biopharma Corporation is involved in the development of antiviral therapies and vaccines, making it a competitor in the infectious disease space targeted by Bavarian Nordic.

About

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Show more...
CEO
Dr. Paul John Chaplin MSc, Ph.D.
Employees
1645
Country
DK
ISIN
DK0015998017

Listings

0 Comments

Share your thoughts

FAQ

What is Bavarian Nordic A/S stock price today?
The current price of BVNKF is $29.71 USD — it has decreased by -3.16% in the past 24 hours. Watch Bavarian Nordic A/S stock price performance more closely on the chart.
What is Bavarian Nordic A/S stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bavarian Nordic A/S stocks are traded under the ticker BVNKF.
Is Bavarian Nordic A/S stock price growing?
BVNKF stock has fallen by -3.16% compared to the previous week, the month change is a +1.36% rise, over the last year Bavarian Nordic A/S has showed a +41.48% increase.
When is the next Bavarian Nordic A/S earnings date?
Bavarian Nordic A/S is going to release the next earnings report on May 13, 2026.
What were Bavarian Nordic A/S earnings last quarter?
BVNKF earnings for the last quarter are 0.2 USD per share, whereas the estimation was -0.23 USD resulting in a +190.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bavarian Nordic A/S revenue for the last year?
Bavarian Nordic A/S revenue for the last year amounts to 1.61B USD.
What is Bavarian Nordic A/S net income for the last year?
BVNKF net income for the last year is 275.59M USD.
How many employees does Bavarian Nordic A/S have?
As of April 04, 2026, the company has 1,645 employees.
In which sector is Bavarian Nordic A/S located?
Bavarian Nordic A/S operates in the Health Care sector.
When did Bavarian Nordic A/S complete a stock split?
The last stock split for Bavarian Nordic A/S was on January 20, 2016 with a ratio of 3:1.
Where is Bavarian Nordic A/S headquartered?
Bavarian Nordic A/S is headquartered in Hellerup, DK.